SILENCE THERAPEUTICS PLC's ticker is SLN and the CUSIP is 82686Q101. A total of 30 filers reported holding SILENCE THERAPEUTICS PLC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,669,873 | +78.5% | 2,104,875 | 0.0% | 3.04% | +60.4% |
| Q2 2023 | $11,576,813 | -11.3% | 2,104,875 | 0.0% | 1.90% | -25.4% |
| Q1 2023 | $13,050,225 | -59.3% | 2,104,875 | 0.0% | 2.54% | -55.1% |
| Q4 2022 | $32,099,344 | +52.0% | 2,104,875 | 0.0% | 5.66% | -10.6% |
| Q3 2022 | $21,122,000 | – | 2,104,875 | – | 6.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 1,312,233 | $8,135,845 | 3.37% |
| TCG Crossover Management, LLC | 2,104,875 | $13,050,225 | 2.54% |
| M28 Capital Management LP | 145,900 | $904,580 | 1.02% |
| Lombard Odier Asset Management (Europe) Ltd | 3,293,405 | $20,419,111 | 1.01% |
| Deep Track Capital, LP | 1,951,580 | $12,099,796 | 0.50% |
| Lombard Odier Asset Management (USA) Corp | 3,959,101 | $20,689,170 | 0.46% |
| Frazier Life Sciences Management, L.P. | 881,173 | $5,463,273 | 0.40% |
| BVF INC/IL | 1,508,416 | $9,352,179 | 0.34% |
| Parkman Healthcare Partners LLC | 158,774 | $984,399 | 0.21% |
| Artal Group S.A. | 505,074 | $3,131 | 0.19% |